Navigation Links
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
Date:1/30/2013

HAYWARD, Calif., Jan. 30, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it has completed the previously announced underwritten public offering of 60,606,061 shares of its common stock, offered at a price of $0.66 per share.  In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 9,090,909 shares.  The gross proceeds to the Company from the sale of shares in this offering, before deducting customary underwriting discounts and commissions, were $40.0 million.  Anthera intends to use the net proceeds from this offering for general corporate purposes. 

Jefferies & Company, Inc. is acting as sole book-running manager in the offering and Leerink Swann LLC is acting as co-manager.  Trout Capital LLC has acted as an advisor to the Company.

The securities described above were offered by the Company pursuant to a shelf registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC").  A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov.  Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about the Company's expectations with respect to its public offering, including statements about its intended use of proceeds from the offering.  Such statements are based on the Company's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to  those set forth in the Company's public filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.  The Company disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
2. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
3. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
4. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
5. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
6. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
7. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
10. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
11. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... , April 26, 2016 Hill-Rom Holdings, Inc. ... a management presentation at the Deutsche Bank 41 st ... 2:50 p.m. EDT. You are invited to listen ... http://ir.hill-rom.com/events.cfm or access it directly at http://edge.media-server.com/m/p/mr4uxgas . ... hour after conclusion of the live event and accessible at ...
(Date:4/26/2016)... DUBLIN , April 26, 2016 ... "Financial Assessment and Credit Risk Analysis of the Biological ... This comprehensive report analyzes the financial assessment ... China . The report provides readers ... key topics all market participants should be aware of. ...
(Date:4/26/2016)... April 26, 2016 ... 2016;9(1):16-20 DOI: http://doi.org/10.17925/USOR.2016.09.01.16 ... Published recently in US Ophthalmic Review, ... Davidson discusses how laser cataract surgery ... cataract surgery: the laser fragments the lens ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Sanford Health’s work ... A group of researchers and leaders from Sanford Health were selected to participate ... Its Cultural Impact ” and receive the 2016 Pontifical Key Innovation Award at ...
(Date:4/28/2016)... CA (PRWEB) , ... April 28, 2016 , ... La ... currently number one in Central America and is looking to grow their market share ... for such an exceptional brand as La Sirena Foods and indirectly with ...
(Date:4/28/2016)... ... 28, 2016 , ... Head Over Heels Athletic Arts’ gymnast, Brooklyn Varize, has ... be held at the University of Montana on April 28-May 1. Varize will compete ... , In order to qualify, Varize needed to place top seven all-around in her ...
(Date:4/28/2016)... ... April 28, 2016 , ... The ... a new CDISC standard, Clinical Trial Registry (CTR) XML. Clinical trial registries ... will make it possible to build applications that generate submissions for multiple, ...
(Date:4/28/2016)... ... 28, 2016 , ... Cosmetic Town, an online plastic surgery community, announces the ... was recently revamped and upgraded to allow even more interaction between doctors and patients ... , According to the senior editor of Cosmetic Town, “We are excited that our ...
Breaking Medicine News(10 mins):